Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 14/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2392716 | 0.89 | PIK3CD (0.43) | PIK3CDHDAC1PIK3CGCYP3A4PIK3R1 | |
| SCHEMBL12267966 | 0.89 | TSHR (0.43) | PIK3CDHDAC1PIK3CGCYP3A4PIK3R1 | |
| SCHEMBL2109797 | 0.88 | PIK3CD (0.49) | PIK3CDHDAC1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL2396867 | 0.87 | HRH3 (0.48) | PIK3CDHDAC1PIK3CGCYP3A4PIK3CA | |
| SCHEMBL2398167 | 0.85 | HRH3 (0.46) | PIK3CDHDAC1PIK3CGCYP3A4PIK3CA | |
| SCHEMBL2396327 | 0.84 | HRH3 (0.43) | PIK3CDHDAC1PIK3CGCYP3A4PIK3R1 | |
| SCHEMBL2396203 | 0.83 | POLB (0.42) | PIK3CDHDAC1PIK3CGCYP3A4PIK3R1 | |
| SCHEMBL2397798 | 0.83 | HRH3 (0.43) | PIK3CDHDAC1PIK3CGCYP3A4PIK3R1 | |
| SCHEMBL2394343 | 0.83 | HDAC1 (0.39) | PIK3CDHDAC1PIK3CG | |
| SCHEMBL2394808 | 0.82 | HRH3 (0.40) | PIK3CDHDAC1PIK3CGCYP3A4PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2215090-B1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
| EP-2215090-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009053716-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | PIK3CA, PIK3CD, PI4KA | PIK3CD 2/4885HDAC1 3008/4885PIK3CG 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.